Milton D. Gross

TL;DR: The preliminary data in a small number of cases suggests that there are a group of patients with SPB (local disease) in whom FDG PET/CT may detect other unsuspected sites of bone involvement, upstaging the extent of the disease.

TL;DR: Assessing the prognostic factors and survival rate in a large cohort of patients treated and followed up in the same center found that the extent of primary surgery and the presence of I-131 positive or negative metastases have similar prognostic significance.

TL;DR: In this study, 18F-FDG PET/CT was the most sensitive imaging modality in detecting metastases in recurrent MTC patients with increased serum calcitonin levels and was useful in some patients to plan a more accurate re-operation.

TL;DR: There was congruence between the anatomic (CT) and functional (NP-59 scintigraphy and AVC) investigations that depicted asymmetry of the adrenal glands which were not associated with abnormalities of overall adrenal function or hypothalamic-pituitary-adrenal axis integrity.

TL;DR: The developed monoclonal antibody, designated MET4, accurately and reproducibly measures c-MET expression by IHC in FFPE tissues and can be used for molecular imaging in vivo, encourage further development of MET4 as a multipurpose molecular diagnostics reagent to help to guide appropriate selection of patients being considered for treatment with c- MET–antagonistic drugs.